JP2023500326A5 - - Google Patents

Info

Publication number
JP2023500326A5
JP2023500326A5 JP2022525704A JP2022525704A JP2023500326A5 JP 2023500326 A5 JP2023500326 A5 JP 2023500326A5 JP 2022525704 A JP2022525704 A JP 2022525704A JP 2022525704 A JP2022525704 A JP 2022525704A JP 2023500326 A5 JP2023500326 A5 JP 2023500326A5
Authority
JP
Japan
Prior art keywords
combination according
inhibitor
administered
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500326A (ja
JP7767279B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058718 external-priority patent/WO2021091904A1/en
Publication of JP2023500326A publication Critical patent/JP2023500326A/ja
Publication of JP2023500326A5 publication Critical patent/JP2023500326A5/ja
Priority to JP2025009336A priority Critical patent/JP2025061603A/ja
Application granted granted Critical
Publication of JP7767279B2 publication Critical patent/JP7767279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525704A 2019-11-04 2020-11-03 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 Active JP7767279B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009336A JP2025061603A (ja) 2019-11-04 2025-01-22 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930251P 2019-11-04 2019-11-04
US62/930,251 2019-11-04
PCT/US2020/058718 WO2021091904A1 (en) 2019-11-04 2020-11-03 Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009336A Division JP2025061603A (ja) 2019-11-04 2025-01-22 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2023500326A JP2023500326A (ja) 2023-01-05
JP2023500326A5 true JP2023500326A5 (cg-RX-API-DMAC7.html) 2023-11-14
JP7767279B2 JP7767279B2 (ja) 2025-11-11

Family

ID=75848061

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525704A Active JP7767279B2 (ja) 2019-11-04 2020-11-03 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2025009336A Pending JP2025061603A (ja) 2019-11-04 2025-01-22 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009336A Pending JP2025061603A (ja) 2019-11-04 2025-01-22 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Country Status (11)

Country Link
US (2) US12391946B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054594A4 (cg-RX-API-DMAC7.html)
JP (2) JP7767279B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220130669A (cg-RX-API-DMAC7.html)
CN (1) CN115666588A (cg-RX-API-DMAC7.html)
AU (1) AU2020380245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3156376A1 (cg-RX-API-DMAC7.html)
IL (1) IL292596A (cg-RX-API-DMAC7.html)
MX (1) MX2022005354A (cg-RX-API-DMAC7.html)
TW (1) TW202133854A (cg-RX-API-DMAC7.html)
WO (1) WO2021091904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6162709B2 (ja) * 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
KR102242077B1 (ko) * 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
PT3456333T (pt) 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
US20150342982A1 (en) * 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms

Similar Documents

Publication Publication Date Title
JP2016504307A5 (cg-RX-API-DMAC7.html)
Bahador et al. From therapy to experimental model: a hundred years of endotoxin administration to human subjects
Savarese et al. Prevention of chemotherapy and radiation toxicity with glutamine
Freyer et al. Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?
KR20200027548A (ko) 병용 암 요법
JP2012521435A5 (cg-RX-API-DMAC7.html)
JP2018517686A5 (cg-RX-API-DMAC7.html)
RU2017143776A (ru) Пролекарства альвоцидиба, имеющие повышенную биодоступность
JP2014144962A5 (cg-RX-API-DMAC7.html)
JP2009530295A5 (cg-RX-API-DMAC7.html)
Tewes et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study
Zhang et al. Combination chemotherapy with low‐dose cytarabine, homoharringtonine, and granulocyte colony‐stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia
Wei et al. Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy.
Evans et al. VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group
Ferreri et al. Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.
JP6895688B2 (ja) 血液がんの新規治療法及び新規治療剤
Lee et al. Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
Georgoulias et al. Docetaxel versus docetaxel/cisplatin in patients with advanced non–small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
Anderson et al. Comparison of radiotherapy alone and radiotherapy with chemotherapy using adriamycin and 5-fluorouracil in bronchogenic carcinoma.
Roncadin et al. Feasibility of total body irradiation in chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphomas
US20210315898A1 (en) Combination therapy for treating cancer
WO2021172490A1 (ja) 組み合わせ医薬、およびピリミジン代謝拮抗剤の耐性化の予防または抑制薬
Wu et al. Administration of amifostine in the stage of remission induction can benefit the patients with hematological malignancy in autologous stem cell transplantation: a retrospective study
Holmes et al. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer